Arcellx, Inc. $ACLX Shares Acquired by Rhumbline Advisers

Rhumbline Advisers increased its holdings in Arcellx, Inc. (NASDAQ:ACLX) by 6.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,751 shares of the company’s stock after acquiring an additional 3,848 shares during the quarter. Rhumbline Advisers owned approximately 0.12% of Arcellx worth $4,182,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its stake in Arcellx by 104.1% in the 1st quarter. GAMMA Investing LLC now owns 494 shares of the company’s stock valued at $32,000 after buying an additional 252 shares during the period. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Arcellx during the 1st quarter worth $50,000. GF Fund Management CO. LTD. purchased a new position in Arcellx during the 4th quarter worth $87,000. Amalgamated Bank raised its position in Arcellx by 12.0% during the 1st quarter. Amalgamated Bank now owns 1,508 shares of the company’s stock worth $99,000 after buying an additional 161 shares during the last quarter. Finally, Covestor Ltd raised its position in Arcellx by 47.6% during the 1st quarter. Covestor Ltd now owns 2,137 shares of the company’s stock worth $140,000 after buying an additional 689 shares during the last quarter. 96.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on ACLX. Citigroup began coverage on shares of Arcellx in a research report on Tuesday, June 17th. They set a “buy” rating and a $110.00 price objective for the company. Cantor Fitzgerald upgraded shares of Arcellx to a “strong-buy” rating in a research report on Monday, August 4th. Scotiabank upped their price objective on shares of Arcellx from $93.00 to $133.00 and gave the stock a “sector outperform” rating in a research report on Thursday, July 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $115.00 price target on shares of Arcellx in a research note on Monday, June 16th. Two equities research analysts have rated the stock with a Strong Buy rating and thirteen have assigned a Buy rating to the stock. According to data from MarketBeat.com, Arcellx currently has an average rating of “Buy” and a consensus target price of $114.31.

Arcellx Stock Down 1.9%

NASDAQ:ACLX opened at $76.19 on Monday. The stock has a market cap of $4.23 billion, a PE ratio of -22.28 and a beta of 0.28. Arcellx, Inc. has a fifty-two week low of $47.86 and a fifty-two week high of $107.37. The firm’s fifty day simple moving average is $70.73 and its 200-day simple moving average is $66.40.

Arcellx (NASDAQ:ACLX) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.09. The firm had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $16.76 million. Arcellx had a negative net margin of 329.93% and a negative return on equity of 43.04%. Equities analysts anticipate that Arcellx, Inc. will post -1.58 earnings per share for the current year.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).